Ornella Garrone

[Ornella Garrone @orniti]

https://t.co/bQJwcU7Rbo

[Policlinico di Milano @policlinicoMI]

#CONVEGNO Il tumore della mammella al centro dell'evento, accreditato #ECM, “#BreastCancer in Autumn 2026 – 4th edition”, con responsabile scientifica Ornella Garrone, direttrice #Oncologia Medica e coordinatrice della #BreastUnit di #PoliclinicoMi
➡���https://t.co/XnSvWDwtQL

[Paolo Tarantino @PTarantinoMD]

The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation.

[Dr Rupam Manna MD @DrRupamOncology]

🔄 Tamoxifen → Aromatase Inhibitor (AI) switch
& safely stopping Ovarian Function Suppression (OFS)
in HR+ Breast Cancer — hormone levels are your guide.
✅ E2 & FSH thresholds
✅ Natural menopause vs chemo-induced amenorrhea
✅ When you CAN switch to AI alone
✅ When you MUST continue tamoxifen or AI + OFS
✅ Practical ASCO/NCCN algorithm & monitoring tips
📌 Full decision-making infographic 👇
#BreastCancer #Oncology #EndocrineTherapy #HRPositive #CancerEducation
Follow for more visual oncology tools → @DrRupamOncology

[ESMO Open @ESMO_Open]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia in @ESMO_Open. 969 pts, 6 studies: consistent safety profile, some differences between NA/Europe and Asia. https://t.co/Ovq4fKsgRX

[Paolo Tarantino @PTarantinoMD]

TROPION-Breast02 published in @Annals_Oncology: 1L therapy with Dato-DXd led to near doubling of PFS, ORR and significant OS benefit (vs chemo) in IO-ineligible mTNBC. New important option and new hope for one of the most aggressive forms of breast cancer. https://t.co/a7p4ivlYDW

[Ornella Garrone @orniti]

@elonmuskTN 68

[Sherene Loi, MD @LoiSher]

🚩🚩important to see that the Ribo benefit continues now that all patients have completed the 3yrs of treatment.

Interestingly, the lower risk patients have similar absolute benefit. There will be an OS update at #ESMO25 presented with the MonarchE OS data-- apparently now significant- given the OS curves were the overlapping at last reporting both studies should be very interesting viewing! #BCSM

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

This recent study looked at the association between young age at #MetastaticBreastCancer diagnosis and overall survival in the #EMBRACE study. The study included 4000+ pts with de novo and recurrent #MBC and found that:
📌 Age ≤35 years at MBC diagnosis was associated with worse overall survival (OS) after adjustment for clinicopathological prognostic features, compared to middle-age (45–55 years at diagnosis).
📌The relationship between young age and OS appeared to be dependent on tumor molecular subtype, with significant associations observed among individuals with HER2−, luminal B-like metastatic tumors.
👉Further investigation of the potential biologic and treatment/access to care mechanisms at play is needed.
🔓https://t.co/2pUdX0Ebc1
@VarellaLeticia1 @stolaney1 @drsarahsam @AnnPartridgeMD @nlinmd #BreastCancer

[Policlinico di Milano @policlinicoMI]

#RoadToNewPoliclinico
Stanze singole per tutelare la degenza di chi è in cura per un tumore: nel nuovo #PadiglioneSforza il reparto di #OncologiaMedica è una novità importante perché agevola la continuità di cura e la tempestività di intervento
#NuovoPoliclinico #PoliclinicoMi

[Ornella Garrone @orniti]

@curijoey Totally agree!

[Ornella Garrone @orniti]

@ScaltritiLab Auguri!

[NEJM @NEJM]

Original Article: Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy (phase 3 trial) https://t.co/M5HIEFodxB

#Oncology

[Ornella Garrone @orniti]

@FAndreMD @FondazioneBona1 @myESMO @VilledeNice Rest in peace dear friend

[ONcotwITting @ONcotwITting]

Sorveglianza mammografica dopo una diagnosi di carcinoma mammario: serve davvero ogni anno? https://t.co/l9Yz6rOsGG

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟🔍 SCORPIO: A machine learning model to predict immunotherapy efficacy using clinical and lab data 🔬💡🌟💫
@Nature @OncoAlert
🔹 Assesses ICI efficacy without the need for advanced genomic or immunologic tests.
🔹 Outperforms TMB and PD-L1 in predicting overall survival and clinical benefit.
🔹 Validated in 9,745 cancer patients across multiple cohorts.
🔹 Provides a low-cost, accessible tool for therapeutic decision-making in oncology.

🔹 SCORPIO is a machine learning model designed to predict the efficacy of immune checkpoint inhibitors (ICIs) without requiring advanced genomic or immunologic assays.

🔹 Outperforms TMB and PD-L1 in predicting overall survival and clinical benefit in patients treated with ICIs.

🔹 Validated in 9,745 patients across 21 cancer types, using data from MSKCC, MSHS, and 10 phase 3 clinical trials.

🔹 AUC for Overall Survival:
◽ SCORPIO: 0.763 - 0.759
◽ TMB: 0.503 - 0.543

🔹 AUC for Clinical Benefit:
◽ SCORPIO: 0.714 - 0.641
◽ TMB: 0.546 - 0.573

🔹 SCORPIO’s Advantages:
◽ Based on routine clinical and blood test data 🩸
◽ Cost-effective and widely accessible 💰
◽ Applicable in hospitals without advanced testing capabilities 🏥
◽ Generalizable across multiple cancer types 🎯

🔹 Clinical Applications:
◽ Helps guide treatment decisions between ICIs, chemotherapy, and other therapies.
◽ Enables personalized patient selection based on predicted risk and benefit.

📌 Reference: @NatureMedicine
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@yekeduz_emre
@kidneycan
#Oncology #Immunotherapy #MachineLearning #SCORPIO #CheckpointInhibitors

https://t.co/GqpSwOz9b5

[Elisa Agostinetto @ElisaAgostinett]

Adjuvant ribociclib has been approved by EMA for HR+/HER2- early breast cancer, based on the results of NATALEE

Industry press release⬇️

@OncoAlert

https://t.co/ma77QPUsKw

[soria @jsoriamd]

Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer & 3 for non-oncology indications. This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell & checkpoint inhibitors.https://t.co/L4qdRTL5Cr

[Elisa Agostinetto @ElisaAgostinett]

Does physical activity play an immumomodulatory role in breast cancer? 🏃🏼‍♀️‍➡️���🏽‍♀️

In this🇮🇹work by @orniti et al. out in @ESMO_Open, physical activity ⬇️ cytokine levels during neoadjuvant CT and was associated with ��️ pCR

@OncoAlert

https://t.co/BorjnGOr1Z

[Carmen Criscitiello @CarmenCriscit]

Exciting news! The Phase 3 KEYNOTE-522 trial met its OS endpoint in high-risk early-stage TNBC patients. This confirms the therapy's extraordinary potential in saving lives. #bcsm #TNBC